Tumor Biology

, Volume 34, Issue 5, pp 2565–2572 | Cite as

Association between MTHFR Ala222Val (rs1801133) polymorphism and bladder cancer susceptibility: a systematic review and meta-analysis

  • Kai Li
  • Yong ping Hu
  • Zecheng Yang
  • Tongxin Sun
Research Article


Folate metabolism is thought to play an important role in carcinogenesis through its involvement in both DNA methylation and nucleotide synthesis. The association between the MTHFR Ala222Val polymorphism and bladder cancer has been widely reported, however, in general the data from published studies with individually low statistical power were controversial and underpowered. Hence, we performed a meta-analysis to investigate the association between bladder cancer and MTHFR Ala222Val in different inheritance models. Fourteen studies including a total of 3,570 bladder cancer cases and 3,926 controls for MTHFR rs1801133 polymorphism were included in the meta-analysis. Data were extracted from these studies and odds ratios with corresponding 95 % confidence intervals (95 % CI) were computed to estimate the strength of the association. Overall, the MTHFR Ala222Val polymorphism was not associated with the development of bladder cancer in all genetic models (Ala/Ala vs. Val/Val—OR = 0.961, 95 % CI = 0.763–1.209; Ala/Ala vs. Ala/Val—OR = 0.918, 95 % CI = 0.795–1.060—Ala/Val vs. Val/Val—OR = 1.022, 95 % CI = 0.852–1.227; dominant model—OR = 0.998, 95 % CI = 0.869–1.145; recessive model—OR = 0.921, 95 % CI = 0.794–1.069; Ala allele vs. Val allele—OR = 0.957, 95 % CI = 0.857–1.067). In the stratified analyses, no significant associations were found among different descent populations and sources of controls. Our meta-analysis suggests that the MTHFR Ala222Val polymorphism not contributes to the development of bladder cancer.


Bladder cancer MTHFR Polymorphism Susceptibility Meta-analysis 


Conflicts of interest



  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin. 2001;51:15–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Silverman DT. Bladder cancer: biology, diagnosis and management. New York: Oxford University Press; 1999. p. 11–55.Google Scholar
  3. 3.
    Cohen SM, Shirai T, Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl. 2000;205:105–15.CrossRefPubMedGoogle Scholar
  4. 4.
    Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89:630–9.CrossRefPubMedGoogle Scholar
  5. 5.
    St Clair DK, Jordan JA, Wan XS, Gairola CG. Protective role of manganese superoxide dismutase against cigarette smoke-induced cytotoxicity. J Toxicol Environ Health. 1994;43:239–49.CrossRefPubMedGoogle Scholar
  6. 6.
    García-Closas R, García-Closas M, Kogevinas M, Malats N, Silverman D, Serra C, et al. Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. Eur J Cancer. 2007;43:1731–40.CrossRefPubMedGoogle Scholar
  7. 7.
    Mannino DM, Mulinare J, Ford ES, Schwartz J. Tobacco smoke exposure and decreased serum and red blood cell folate levels: data from the third national health and nutrition examination survey. Nicotine Tob Res. 2003;5:357–62.CrossRefPubMedGoogle Scholar
  8. 8.
    Tungtrongchitr R, Pongpaew P, Soonthornruengyot M, Viroonudomphol D, Vudhivai N, Tungtrongchitr A, et al. Relationship of tobacco smoking with serum vitamin B-12, folic acid and haematological indices in healthy adults. Public Health Nutr. 2003;6:675–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome. 1998;9:652–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.CrossRefPubMedGoogle Scholar
  11. 11.
    Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T polymorphism in methynetetrahy-drofolate reductase (MTHFR): its frequency impact on plasma homocysteine concentration in different European populations: EARS group. Atherosclerosis. 1998;136:347–54.CrossRefPubMedGoogle Scholar
  12. 12.
    Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methyle-netetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.CrossRefPubMedGoogle Scholar
  14. 14.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  16. 16.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  17. 17.
    Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7.Google Scholar
  19. 19.
    Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Kimura F, Florl AR, Steinhoff C. Polymorphic methyl group metabolism genes in patients with transitional cell carcinoma of the urinary bladder. Mutat Res. 2001;458:49–54.PubMedGoogle Scholar
  22. 22.
    Sanyal S, Festa F, Sakano S. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Lin J, Spitz MR, Wang Y. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case–control study. Carcinogenesis. 2004;25:1639–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Moore LE, Wiencke JK, Bates MN. Investigation of genetic polymorphisms and smoking in a bladder cancer case–control study in Argentina. Cancer Lett. 2004;211:199–207.CrossRefPubMedGoogle Scholar
  25. 25.
    Karagas MR, Park S, Nelson HH. Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: a population-based case–control study. Int J Hyg Environ Health. 2005;208:321–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Moore LE, Malats N, Rothman N. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer. 2007;120:2452–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Ouerhani S, Oliveira E, Marrakchi R. Methylenetetrahydrofolate reductase and methionine synthase polymorphisms and risk of bladder cancer in a Tunisian population. Cancer Genet Cytogenet. 2007;176:48–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang M, Zhu H, Fu G. Polymorphisms of methylenetetrahydrofolate reductase and methionine synthase genes and bladder cancer risk: a case–control study with meta-analysis. Clin Exp Med. 2009;9:9–19.CrossRefPubMedGoogle Scholar
  29. 29.
    Ouerhani S, Rouissi K, Marrakchi R. Combined effect of NAT2, MTR and MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population. Cancer Detect Prev. 2009;32:395–402.CrossRefPubMedGoogle Scholar
  30. 30.
    Rouissi K, Ouerhani S, Oliveira E. Polymorphisms in one-carbon metabolism pathway genes and risk for bladder cancer in a Tunisian population. Cancer Genet Cytogenet. 2009;195:43–53.CrossRefPubMedGoogle Scholar
  31. 31.
    Cai DW, Liu XF, Bu RG, Chen XN. Genetic polymorphisms of MTHFR and aberrant promoter hypermethylation of the RASSF1A gene in bladder cancer risk in a Chinese population. J Int Med Res. 2009;37:1882–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Safarinejad MR, Shafiei N, Safarinejad S. Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men. Med Oncol. 2010;28 Suppl 1:S398–412.PubMedGoogle Scholar
  33. 33.
    Izmirli M, Inandiklioglu N, Abat D, Alptekin D, Demirhan O, Tansug Z, et al. MTHFR gene polymorphisms in bladder cancer in the Turkish population. Asian Pac J Cancer Prev. 2011;12:1833–5.PubMedGoogle Scholar
  34. 34.
    Fujisawa T, Ikegami H, Kawaguchi Y. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998;41:47–53.CrossRefPubMedGoogle Scholar
  35. 35.
    Liwei L, Chunyu L, Ruifa H. Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis. Urology. 2009;74:884–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Kai Li
    • 1
  • Yong ping Hu
    • 2
  • Zecheng Yang
    • 3
  • Tongxin Sun
    • 4
  1. 1.Department of Urology, The Third Center HospitalTianjinPeople’s Republic of China
  2. 2.Department of UrologyLaizhou People’s HospitalLaizhouPeople’s Republic of China
  3. 3.Breast Surgery Department2nd Hospital of Jilin UniversityChangchunPeople’s Republic of China
  4. 4.Department of UrologyThe Second Hospital of Tianjin Medical UniversityTianjinPeople’s Republic of China

Personalised recommendations